
	Where results make sense

Topic: Amgen

Related Topics

Diosynth

Genentech

Alza

Biogen Idec

Lundbeck

AstraZeneca

Green biotechnology

Avaya

FedEx

Abbott Laboratories

Gilead Sciences

Takeda Pharmaceuticals

Novo Nordisk

Akzo Nobel

GlaxoSmithKline

In the News (Sun 27 May 12)

EXECUTIVE POWER

Iran

ANALYSIS

Pakistan

Family compact

	Amgen - Investors - Fact Sheets
		A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.
		Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.
		Amgen is providing this information as of January 26, 2006, and does not undertake any obligation to update any of the information contained in this document as a result of new information, future events or otherwise.
	www.amgen.com /investors/fact_sheets.html (1829 words)

	Amgen's Osteoporosis Drug Aims at Merck
		Amgen (AMGN:Nasdaq - commentary - research) is gearing up to present additional clinical data on its experimental osteoporosis treatment AMG 162 -- one of the biotech giant's most promising late-stage drug candidates.
		Amgen will be presenting updated results from this phase II study at two upcoming medical meetings: the American Society of Bone and Mineral Research meeting, Oct. 1-5, and the annual meeting of the American College of Rheumatology, scheduled for Oct. 16-21.
		Amgen is counting on experimental drugs like AMG 162 to provide the fuel for medium- and long-term earnings growth.
	www.thestreet.com /_more/comment/adamfeuerstein/10184302.html (358 words)

	BIO.COM: Biotechnology & Pharmaceutical News, Jobs, Software, Reports, Books, Events
		Amgen, the world's largest independent biotechnology company, is dedicated to bringing meaningful improvement to the lives of patients worldwide.
		Amgen's values are the foundation of our culture and create the environment in which we work.
		Amgen is headquartered in Thousand Oaks, California and is conveniently located an hour's drive west of Los Angeles and just inland from the Pacific Ocean.
	www.bio.com /industryanalysis/industryanalysis_profiles.jhtml?action=view&id=c6390 (338 words)

	Amgen is at the top (Site not responding. Last check: 2007-10-22)
		Amgen's Aranesp, an anemia drug, was cleared by the FDA in September.
		Amgen's recent acquisition of Immunex will help fuel growth in that area, a primary strength for the Seattle biotech.
		Immunex executives said after the merger was proposed that Amgen could bring its inflammation and immunology research to Seattle, where Immunex is building a $750 million waterfront complex.
	seattlepi.nwsource.com /business/57164_amgen06.shtml (902 words)

	Amgen "overweight" \| newratings.com (Site not responding. Last check: 2007-10-22)
		Amgen is a global biotechnology company that develops and manufactures human therapeutics.
		Amgen's operating leverage is expected to be enhanced with the launch of Sensipar, paliferman, and panitumumab, in the near term, the analysts add.
		According to Prudential Financial, Amgen is poised to benefit from the 2006 Medicare drug benefit, driven by Sensipar and Enbrel.
	www.newratings.com /analyst_news/article_422174.html (316 words)

	Boston.com / Business / ViaCell, Amgen partner in cell therapies deal
		For Amgen -- it's the world's largest biotech firm, with product sales expected to reach more than $7.5 billion this year -- the deal is one of an expected flurry of transactions with smaller biotechs intended to fill the company's product pipeline.
		Amgen recently held a meeting with about 100 chief executives of smaller biotechs from the San Francisco area.
		Beer said a key step toward sealing the deal with Amgen was the start of the clinical trial involving CB001, a potential treatment for adults with leukemia and other cancers of the blood, which began enrolling patients this month.
	www.boston.com /business/globe/articles/2003/12/31/viacell_amgen_partner_in_cell_therapies_deal (821 words)

	9news.com \| News \| Amgen seals deal to buy Abgenix for $2.2 billion (Site not responding. Last check: 2007-10-22)
		The purchase gives Amgen full ownership of panitumumab, a drug for colon, head and neck cancers the companies have been developing jointly since 2002 under an agreement Amgen assumed with its purchase of Immunex.
		Amgen, near Los Angeles, is the biggest biotech based on revenue, with $10.6 billion in sales last year.
		Amgen said it expected the deal to close in the first quarter of next year.
	www.9news.com /acm_news.aspx?OSGNAME=KUSA&IKOBJECTID=2f7f90bb-0abe-421a-01bc-c4da0fc58e28&TEMPLATEID=0c76dce6-ac1f-02d8-0047-c589c01ca7bf (429 words)

	Inaugural Amgen Tour of California (Site not responding. Last check: 2007-10-22)
		California will provide the stunning backdrop for the inaugural Amgen Tour of California in February 2006, a professional cycling race modeled after the Tour de France, the details of which were announced by race presenter AEG today.
		Amgen, Inc, the world's leading biotechnology company (based in Thousand Oaks, Calif.), is the race's title sponsor.
		The Amgen Tour of California is sanctioned by the USA Cycling and UCI (Union Cycliste Internationale), an international non-profit organization that regulates the sport of cycling.
	www.outdoornewswire.com /v/current/htdocs/etc/sa.php/63617465676f72794e616d653d4d746e2042696b696e672663617465676f72794c6162656c3d4d746e42696b696e67266c6f636174696f6e3d323030352f31312f313133323637363931382672737349643d32313135 (784 words)

	SPOTLIGHT (Site not responding. Last check: 2007-10-22)
		Amgen's stock price has increased more than 50% in the last three months and more than doubled in the last 12 months.
		Amgen has a virtual monopoly on this product; as your primary customer for it in the U.S., and as a "partner," we believe we deserved more consideration in your decision-making process.
		Furthermore, Amgen chose not to renew its membership in NRAA when it came due for renewal in June 1999.
	www.eneph.com /html/news400.htm (2114 words)

	Amgen to Acquire Abgenix for $22.50 Per Share
		Amgen has been intimately involved in all aspects of the development and commercialization of panitumumab over the last few years, providing us with substantial and realistic insight into the value of, and significant opportunities for, this cancer therapeutic.
		Amgen expects dilution of adjusted earnings per share in 2006 and 2007 in the range of $0.05 to $0.10, with impact to adjusted earnings per share expected to be accretive thereafter, assuming commercial success of panitumumab.
		Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, sales growth of recently launched products, difficulties or delays in manufacturing our products, and regulatory developments (domestic or foreign) involving current and future products and manufacturing facilities.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-14-2005/0004234277&EDATE= (1906 words)

	Acquisition Announcement (Site not responding. Last check: 2007-10-22)
		Amgen will acquire Immunex in a tax-free reorganization, and the Immunex shareholders will not be taxed to the extent that they exchange their Immunex stock for Amgen stock.
		Amgen is a leading global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.
		Amgen, Immunex and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Amgen and Immunex in favor of the acquisition.
	amgen.acquisitioninformation.com (2429 words)

	The Seattle Times: Business & Technology: Amgen expects lift from anemia drug (Site not responding. Last check: 2007-10-22)
		Amgen is counting on Aranesp and two other drugs with more than $1 billion in sales, the cancer treatment Neulasta and the arthritis medicine Enbrel, which Amgen acquired when it bought Seattle-based Immunex a year ago.
		Amgen has gained in Europe after some patients who received Johnson and Johnson's Eprex died from a rare blood disease linked to the drug.
		Amgen said, excluding certain costs, it will earn as much as $2.40 a share in 2004, which is 1 cent higher than the average estimate of analysts.
	seattletimes.nwsource.com /html/businesstechnology/2001815975_amgen16.html (411 words)

	BioWorld Today
		Tularik's operations in South San Francisco are about 400 miles north of Amgen's offices in Thousand Oaks, Calif. Amgen, which holds a 21 percent stake in Tularik, would own 100 percent of the company upon the completion of the transaction expected in the second half of this year.
		Amgen expects to incur a one-time charge related to in-process research and development.
		Amgen, founded in 1980, is considered a harbinger of the biotech industry, with a worldwide staff of more than 10,000 employees and annual revenues of $5.5 billion in 2002.
	www.bioworld.com /servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=32418 (940 words)

	BostonWorks Hiring Hub: Amgen Case Study
		Amgen is headquartered in Thousand Oaks, California, and is the world's largest biotechnology company.
		Amgen develops therapeutic drugs in the areas of hematology, oncology, inflammation, neurology and metabolic disorders.
		Amgen anticipated the new site would grow from 300 employees to 1,200 in 18 months.
	bostonworks.boston.com /mediakit/case_studies/amgen (351 words)

	Amgen pursues partner / Biotech giant offers $2.2 billion for Fremont's Abgenix
		Amgen executives said the decisive factor behind the purchase offer was the potential for the cancer drug candidate panitumumab, which delayed the advance of colon cancer by 46 percent among a class of the sickest patients who were receiving no further benefit from chemotherapy.
		Amgen is betting that the drug, a monoclonal antibody discovered through Abgenix's proprietary tribe of genetically engineered mice, could offer even greater advantages to patients who get it earlier.
		Amgen estimates the merger would dilute its adjusted earnings per share by 5 to 10 cents in 2006 and 2007 but boost earnings after that if panitumumab succeeds.
	www.sfgate.com /cgi-bin/article.cgi?f=/c/a/2005/12/15/BUGNHG87711.DTL&feed=rss.business (547 words)

	Amgen Buys a Potential Blockbuster
		That raises a question: Is Amgen's stock still the bargain that the majority of the 30 analysts who cover it have been saying it is? Amgen expects the deal to close in 2006 and to reduce earnings-per-share estimates by somewhere between 5 cents and 10 cents in 2006 and 2007.
		Amgen is still enjoying double-digit percentage growth in sales of its drugs to treat rheumatoid arthritis, anemia, and infections in patients undergoing chemotherapy.
		Amgen CEO Kevin Sharer admits that the company won't make the original target, but he points out that Enbrel is likely to exceed $3 billion in sales next year.
	www.businessweek.com /technology/content/dec2005/tc20051216_568875.htm?campaign_id=rss_tech (1456 words)

	Fool.com: Is Amgen a Rule Maker? (Rule Maker) December 6, 1999
		Amgen does have a fat drug pipeline with four late-stage compounds with good chances to hit the market in the next two years.
		Amgen has averaged 12.05% sales growth over the last five years, but that pace is accelerating.
		Amgen's gross margin on 1999 sales rings in at 88%, and net margin exceeded 35% in the third quarter and 33% for the current fiscal year to date.
	www.fool.com /portfolios/rulemaker/1999/rulemaker991206.htm (1361 words)

	Executive Briefing: Amgen Moves Beyond Proteins (Site not responding. Last check: 2007-10-22)
		At Amgen, the task is all the more daunting because the majority of profits come from just two molecules: the recombinant proteins epoetin alfa (Epogen) and the growth factor filgrastim (Neupogen), and their improved, follow-on versions.
		Amgen spent $1.6 billion on research last year alone, bringing the total it has spent since 1994 up to a massive $7.9 billion.
		Given the emerging competition for Amgen’s protein blockbusters—a matter of concern for some investors who want to be assured of continued strong revenue growth—it’s smart for Amgen to build new skills that will increase its opportunities to discover valuable drugs.
	www.windhover.com /contents/monthly/exex/e_2004800043.htm (441 words)

	Rivals Laying Siege to Amgen's Near Monopoly in Anemia Drugs - New York Times
		For years, the biotechnology giant Amgen has wielded a near monopoly over its industry's most lucrative franchise, the anemia drugs on which hundreds of thousands of American kidney and cancer patients and their insurers spend billions of dollars each year.
		Some Amgen critics say that while its anemia drugs have truly helped people, its near monopoly is lasting much longer than patent law was meant to allow.
		"Amgen is absolutely determined to ensure that this is the case, that the effective patent life for EPO in the United States will be 32 years," said C. Boyd Clarke, the chief executive of Neose Technologies, which is trying to develop EPO in a way that would get around Amgen's patents.
	www.nytimes.com /2005/12/23/business/23epo.html?ex=1292994000&en=401523d9538caa77&ei=5088&partner=rssnyt&emc=rss (834 words)

	BW Online \| March 22, 2004 \| Amgen Opens The Secret Curtain
		Amgen Inc. (AMGN) is used to its perch at the pinnacle of biotechnology.
		Perlmutter, a veteran of Merck and Co. (MRK), says Amgen may soon be ready to start clinical trials for a drug to treat neuropathic pain, which occurs when injured nerves send faulty signals to the brain.
		For example, in the field of inflammation, both Amgen and its biggest competitor, Johnson and Johnson (JNJ), are targeting an enzyme called p38.
	www.businessweek.com /magazine/content/04_12/b3875072.htm (1365 words)

	Fool.com: Q & A on Amgen (Stock Research) March 21, 2000
		In fact, Amgen was one of the initial companies to partner with Celera, and therefore stands to gain from the incredible progress that company is making in sequencing the human genome.
		It is generally thought that Amgen is well-positioned in the case, and a judgment favorable to Amgen is expected.
		If Amgen wins the case, Transkaryotic and HMR would likely either be required to pay Amgen royalties on the sales of their gene-activated Epoetin alfa product or be unable to pursue the commercial applications of the drug.
	www.fool.com /research/2000/foolsden000321.htm (1151 words)

	Johnson Sues Amgen Over Sales Practice - New York Times (Site not responding. Last check: 2007-10-22)
		Amgen sells two other drugs, Neulasta and Neupogen, that increase production of infection-fighting white blood cells and are used to treat a different side effect of chemotherapy.
		Amgen has about 98 percent of the market for white cell boosters, a virtual monopoly, according to the lawsuit.
		Amgen and Johnson & Johnson have been feuding almost ever since Amgen, as a young company in need of cash, licensed Procrit to Johnson & Johnson in 1985.
	www.nytimes.com /2005/10/13/business/13drug.html?ex=1286856000&en=76a577b70326e8eb&ei=5090&partner=rssuserland&emc=rss (560 words)

	Biotech Behemoth - Forbes.com (Site not responding. Last check: 2007-10-22)
		Amgen came along a few generations later, based 30 miles north of Hollywood and pursuing not pills but man-made copies of human proteins to offset shortages of the real thing.
		Amgen shares rose a tepid 3% in 2004, and they have barely budged from where they were in 2000, compared with a 44% rise for Amgen's archrival, Genentech.
		Amgen researchers stumbled on the OPG gene a decade ago when they found a version of it, oddly enough, in the intestines of rat fetuses.
	www.forbes.com /free_forbes/2005/0110/128.html (1194 words)

	Rivals Laying Siege to Amgen's Near Monopoly in Anemia Drugs \| Ocala.com \| Star-Banner \| Ocala, Fla. (Site not responding. Last check: 2007-10-22)
		Amgen also won litigation against Transkaryotic Therapies, a Cambridge, Mass., biotechnology company that produced EPO by activating the dormant EPO gene in cultures of human cells, rather than splicing that gene into hamster cells.
		Amgen filed its suit against Roche in Boston and, as it apparently wished, the case was assigned to Judge Young, who ruled in the company's favor against Genetics Institute and TKT.
		If Amgen cannot win or get an injunction, Roche could begin selling CERA after getting approval from the Food and Drug Administration - at the risk of having to make stiff payments to Amgen if it is later found to have infringed.
	www.ocala.com /apps/pbcs.dll/article?AID=/20051223/ZNYT01/512230302/1004/news04 (1757 words)

	Amgen Company Information listing information - BioView (Site not responding. Last check: 2007-10-22)
		Amgen is one of the largest and most successful companies of its kind.
		We believe that Amgen's success -- past and future -- is a direct result of our adherence to these values.
		Amgen's common purpose is best expressed in our aspiration statement: to be the best human therapeutics company.
	www.bioview.com /bv/servlet/BVCompanyDetails;jsessionid=395C2F461BEB2F6D6FDC4EF1CF098061?ID=164435 (334 words)

Try your search on: Qwika (all wikis)